Theralink Technologies, Inc.

www.theralink.com

At Theralink Technologies, our approach is based on more than 16 years of research and development. Our research indicates that genomic and transcriptomic information alone provides an incomplete information resource for physicians to make patient-specific treatment decisions. Our phosphoproteomic RPPA approach is the only platform that quantifies the activation state (phosphorylation) of drug target proteins and their downstream signaling partners within the tumor tissue. Our advanced technology exploits our understanding of the drug-receptor and drug-protein interactions that drive treatment responses. The Theralink assay has been developed to provide physicians with a treatment decision support tool to assist in selecting therapies that are more likely to result in responses to treatment. Our large panel of new protein biomarkers targets therapeutic molecular inhibitors including current FDA approved therapies and certain investigational drugs, making Theralink® an invaluable tool for oncologists and biopharma clinical trials.

Read more

Reach decision makers at Theralink Technologies, Inc.

Lusha Magic

Free credit every month!

At Theralink Technologies, our approach is based on more than 16 years of research and development. Our research indicates that genomic and transcriptomic information alone provides an incomplete information resource for physicians to make patient-specific treatment decisions. Our phosphoproteomic RPPA approach is the only platform that quantifies the activation state (phosphorylation) of drug target proteins and their downstream signaling partners within the tumor tissue. Our advanced technology exploits our understanding of the drug-receptor and drug-protein interactions that drive treatment responses. The Theralink assay has been developed to provide physicians with a treatment decision support tool to assist in selecting therapies that are more likely to result in responses to treatment. Our large panel of new protein biomarkers targets therapeutic molecular inhibitors including current FDA approved therapies and certain investigational drugs, making Theralink® an invaluable tool for oncologists and biopharma clinical trials.

Read more
icon

Country

icon

State

Colorado

icon

City (Headquarters)

Golden

icon

Employees

11-50

icon

Founded

2005

icon

Social

  • icon
  • icon

Employees statistics

View all employees

Potential Decision Makers

  • Vice President , Sales Operations and Strategic Partnerships

    Email ****** @****.com
    Phone (***) ****-****
  • Chief Executive Officer

    Email ****** @****.com
    Phone (***) ****-****
  • Chief Financial Officer

    Email ****** @****.com
    Phone (***) ****-****
  • Director of Biopharma Laboratory

    Email ****** @****.com
    Phone (***) ****-****

Technologies

(19)

Reach decision makers at Theralink Technologies, Inc.

Free credits every month!

My account

Sign up now to uncover all the contact details